Seth Klarman
Baupost Group
Baupost Group 13F holdings
Seth Klarman's Portfolio
- Portfolio value:
- $9.06B≈
- # of securities:
- 31
- Reported for:
- 31 Dec 2019 (Q4)
- Latest filing date:
- 13 Feb 2020
What was Seth Klarman's 2019 Q4 portfolio?
Baupost Group has disclosed a total of 31 security holdings in their (2019 Q4) SEC 13F filing(s) with portfolio value of $9,055,230,000.
Baupost Group's portfolio holdings are tracked quarterly based on SEC 13F filings. Snapshots for each reporting period document the full list of disclosed positions and their portfolio allocations.
Seth Klarman's original 13F reports (2019 Q4) are the official SEC institutional disclosure documents covering all reported equity positions.
29 results
| History | Ticker | Name |
% of portfolio |
Shares* |
Reported price* |
% difference current price* |
Value | Held since* | Held for* |
Security type |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Liberty Global PLC, CL-C
|
12.61%
|
$21.79
|
-56.14%($9.56)
|
2018 Q3
|
≈ 1.50 years
|
Common Stock
|
+19.19% (+8.43M)
|
||||
|
|
Fox Corp, CL-A
|
11.19%
|
$37.07
|
+50.09%($55.64)
|
2015 Q3
|
≈ 4.50 years
|
Common Stock
|
|
||||
|
|
ViaSat Inc
|
11.10%
|
$73.20
|
-1.17%($72.34)
|
2013 Q2 or earlier
|
≈ 6.75+ years
|
Common Stock
|
|
||||
|
|
eBay Inc
|
7.97%
|
$36.11
|
+202.19%($109.12)
|
2018 Q4
|
≈ 1.25 years
|
Common Stock
|
+20.12% (+3.35M)
|
||||
|
|
Paramount Global, CL-B
|
7.88%
|
$41.97
|
|
2018 Q4
|
≈ 1.25 years
|
Common Stock
|
+41.67% (+5M)
|
||||
|
|
Cheniere Energy Inc
|
6.84%
|
$61.07
|
+342.70%($270.36)
|
2014 Q1
|
≈ 6.00 years
|
Common Stock
|
|
||||
|
|
Qorvo Inc
|
3.53%
|
$116.23
|
-25.07%($87.09)
|
2017 Q1
|
≈ 3.00 years
|
Common Stock
|
-51.59% (-2.93M)
|
||||
|
|
Bristol-Myers Squibb Company
|
2.84%
|
$64.19
|
-3.25%($62.10)
|
2019 Q1
|
≈ 1.00 year
|
Common Stock
|
-60.00% (-6M)
|
||||
|
|
THERAVANCE BIOPHARMA INC
|
2.66%
|
$25.89
|
-34.88%($16.86)
|
2014 Q2
|
≈ 5.75 years
|
Common Stock
|
|
||||
|
|
Digitalbridge Group Inc
|
2.61%
|
$19.00
|
-16.42%($15.88)
|
2017 Q1
|
≈ 3.00 years
|
Common Stock
|
|
||||
Completely sold out
4 results
| History | Ticker | Name |
Sold shares* |
% change to portfolio |
Held since* | Held for* |
|---|---|---|---|---|---|---|
|
|
Takeda Pharmaceutical Co Ltd ADR
|
2019 Q1
|
≈ 0.75 years
|
|||
|
|
Antero Resources Corp
|
2014 Q3
|
≈ 5.25 years
|
|||
|
|
Gossamer Bio Inc
|
2019 Q1
|
≈ 0.75 years
|
|||
|
|
Paratek Pharmaceuticals Inc
|
2014 Q4
|
≈ 5.00 years
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.